Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472950 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis
A Phase 2 study, sponsored by University of Kansas Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03472950 is a Phase 2 study that has completed, run by University of Kansas Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT03472950, a Phase 2 study, has completed, sponsored by University of Kansas Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.
Interventions
- DRUG Ranolazine 500 MG
- DRUG Ranolazine 1000 MG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03472950
The ClinicalTrials.gov registry entry for NCT03472950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Kansas Medical Center, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ranolazine 500 MG is the first listed.
NCT03472950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03472950 about?
NCT03472950 is a clinical study titled "Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis". The purpose of this research study is to evaluate the safety and effectiveness of Ranolazine, and how well it is tolerated in patients with Amyotrophic Lateral Sclerosis (ALS). Ranolazine is an FDA approved drug that is used for decreasing chest pain.
What is the current status of trial NCT03472950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-06-11. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT03472950?
The interventions under investigation include: Ranolazine 500 MG (DRUG), Ranolazine 1000 MG (DRUG).
Who is sponsoring clinical trial NCT03472950?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.